Clinical Trial Update: Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial assessing pirfenidone for idiopathic pulmonary fibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2020-11-20